SAN DIEGO, April 1, 2008 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) and its operating unit InnerCool Therapies announced today that InnerCool has entered into a European commercialization agreement with Euromed Medizinisch GmbH (Euromed), a leading distributor of cardiology medical products. Under the terms of the agreement, Euromed will have exclusive marketing, sales and distribution rights in Austria, Germany and Switzerland for InnerCool's portfolio of temperature modulation systems. This agreement covers InnerCool's CoolBlue(TM), a nurse-friendly and cost-effective surface cooling temperature modulation system, which was launched in the U.S. market during the fourth quarter 2007, as well as InnerCool's, premium-priced, high-performance RapidBlue(TM) endovascular cooling system, which is expected to be launched in the U.S. market in the second quarter 2008. Using Euromed's marketing and sales force, sales of CoolBlue consoles and disposables are expected to begin in Europe this quarter, and sales of RapidBlue consoles and disposables are expected to begin next quarter.
"We are pleased to have this distribution agreement with Euromed. They
have a knowledgeable medical sales force with clinical support in our
targeted markets, as well as extensive experience in selling temperature
modulation products," stated Christopher J. Reinhard, Chairman and Chief
Executive Officer of Cardium Therapeutics and InnerCool Therapies. "This
new European partnership, along with our recent distribution agreement for
Australia and New Zealand, are consistent with our strategy of a
|SOURCE Cardium Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved